Key clinical point: Relapse-free rates were higher for patients with neuromyelitis optica spectrum disorder who received tocilizumab compared with azathioprine.
Major finding: After 90 weeks of therapy, 86% of those receiving tocilizumab were relapse-free, compared with 48.1% of those on azathioprine.
Study details: Randomized, open-label head-to-head trial enrolling 118 patients with highly relapsing NMOSD.
Disclosures: The study was funded by Tianjin Medical University, Tianjin, China; Capital Medical University, Beijing; and the National Science Foundation of China. The authors reported no conflicts of interest.
Zhang C et al. ECTRIMS 2019, Abstract 140.